Apollomics reports US$3.9M payment from LaunXP as deal remains in force

Rhea-AI Filing Summary

Apollomics Inc. reported it has received US$3,900,000 from LaunXP related to their collaboration on vebreltinib in Asia (excluding mainland China, Hong Kong and Macau). The company stated the agreement remains in full force and effect, with both parties continuing to perform their obligations. Apollomics also noted this update is incorporated by reference into its registration statements on Form S-8 and Form F-3.

Insights

Biopharma partnerships analyst

$3.9M cash received; collaboration continues

Apollomics disclosed a US$3,900,000 payment from LaunXP tied to their vebreltinib collaboration in Asia (excluding mainland China, Hong Kong and Macau). The company states the agreement remains in effect and both sides are performing obligations.

This indicates cash-in from a partner rather than financing, with no equity issuance noted in the excerpt. The continuation of the agreement suggests ongoing operational alignment around vebreltinib, though the excerpt does not discuss milestones or deployment of funds.

Key reference points are the received amount and the statement that the agreement is in full force and effect. Subsequent filings may provide additional detail on future payments or development progress.

Form 6-K: How Foreign Companies Report to the SEC →

		OMB APPROVAL
		OMB Number:		3235-0116
		Expires:    December 31, 2026
		Estimated average burden
		hours per response		8.7

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October, 2025.

Commission File Number 001-41670

Apollomics Inc.

Not Applicable

(Translation of registrant’s name into English)

989 E. Hillsdale Blvd., Suite 220, Foster City, California 94404

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

Update on the Agreement with LaunXP

Pursuant to the Company’s Form 6-K filed on July 25, 2025 (the “July 2025 6-K”), Apollomics Inc. (“Apollomics” or the “Company”) previously disclosed that LaunXP International Co., Ltd. (“LaunXP”) had not fully satisfied its payment obligations under its agreement with the Company for the development and commercialization of vebreltinib in Asia (excluding mainland China, Hong Kong and Macau) (the “Agreement”). As a result, the Company disclosed that it had notified LaunXP of such breach and that the parties were engaged in discussions to resolve the matter.

By way of update to the disclosure contained in the Company’s Form 6-K filed in July 2025, Apollomics hereby reports that, in connection with the previously disclosed transaction, the Company has recently received a payment of US$3,900,000 from LaunXP. The Agreement remains in full force and effect, and both parties continue to perform their respective obligations and maintain active discussions to advance the ongoing collaboration under the Agreement.

The information in this Form 6-K regarding the Agreement with LaunXP is incorporated by reference into the Company’s registration statements under the Securities Act, including its registration statements on Form S-8 (File No. 333-272559) and Form F-3 (File Nos. 333-278430, 333-278431 and 333-279549), and shall be a part thereof, to the extent not superseded by documents or reports subsequently filed or furnished.

2 of 3

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

APOLLOMICS INC.

(Registrant)

Date October 21, 2025

/s/ Peter Lin

Peter Lin, Chief Financial Officer

3 of 3

FAQ

What did Apollomics (APLM) announce regarding LaunXP?

Apollomics reported receiving US$3,900,000 from LaunXP connected to their vebreltinib collaboration in Asia (excluding mainland China, Hong Kong and Macau).

Is the Apollomics–LaunXP agreement still active?

Yes. Apollomics stated the agreement remains in full force and effect and both parties continue to perform their obligations.

What regions are covered under the LaunXP collaboration for vebreltinib?

The collaboration covers Asia, excluding mainland China, Hong Kong and Macau.

Does Apollomics mention how the US$3.9M will be used?

The excerpt does not describe use of proceeds; it states Apollomics received US$3,900,000 and that the agreement continues.

Is this update linked to Apollomics’ registration statements?

Yes. The update is incorporated by reference into Apollomics’ Form S-8 and Form F-3 registration statements listed in the filing.